Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

SML1974

Sigma-Aldrich

CBLC000 trifluoroacetate

≥95% (HPLC)

Synonym(s):

9H-Carbazole-9-ethanamine, N,N-diethyl-3,6-dinitro- trifluoroacetate, Curaxin CBLC000 trifluoroacetate, N,N-Diethyl-3,6-dinitro-9H-carbazole-9-ethanamine trifluoroacetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H20N4O4 · C2HF3O2
CAS Number:
324780-02-1
Molecular Weight:
470.40
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CCN(CC)CCN1C2=C(C=C([N+]([O-])=O)C=C2)C3=C1C=CC([N+]([O-])=O)=C3.FC(F)(C(O)=O)F

Biochem/physiol Actions

CBLC000 is a potent inhibitor of FACT (facilitates chromatin transcription) complex that activates p53 and suppresses NF-kB without genotoxicity. CBLC000 induces chromatin trapping of FACT both in vitro and in vivo. CBLC000 exhibits brad anticancer activity. CBLC000 analog clinical candidate CBL0137 decreases self-renewal of GBM stem cells (GSC).

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H413

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Skin Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alexander V Gasparian et al.
Science translational medicine, 3(95), 95ra74-95ra74 (2011-08-13)
Effective eradication of cancer requires treatment directed against multiple targets. The p53 and nuclear factor κB (NF-κB) pathways are dysregulated in nearly all tumors, making them attractive targets for therapeutic activation and inhibition, respectively. We have isolated and structurally optimized
Josephine Kam Tai Dermawan et al.
Cancer research, 76(8), 2432-2442 (2016-02-28)
The nearly universal recurrence of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC). To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service